Pseudomonas aeruginosa ventilator-associated pneumonia management

References

• ChastreJFagonJYVentilator-associated pneumoniaAm J Respir Crit Care Med2002165786790311934711
   PubMed Web of Science ®Google Scholar
• KollefMHChastreJFagonJYGlobal prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosaCrit Care Med201442102178218725054674
   PubMed Web of Science ®Google Scholar
• RelloJJubertPVallésJArtigasARuéMNiedermanMSEvaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosaClin Infect Dis19962359739788922788
   PubMed Web of Science ®Google Scholar
• BerthelotPGrattardFMahulPProspective study of nosocomial colonization and infection due to Pseudomonas aeruginosa in mechanically ventilated patientsIntensive Care Med200127350351211355118
   PubMed Web of Science ®Google Scholar
• TumbarelloMDe PascaleGTrecarichiEMClinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patientsIntensive Care Med201339468269223370828
   PubMed Web of Science ®Google Scholar
• MelsenWGRoversMMGroenwoldRHAttributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studiesLancet Infect Dis201313866567123622939
   PubMed Web of Science ®Google Scholar
• SafdarNDezfulianCCollardHRSaintSClinical and economic consequences of ventilator-associated pneumonia: a systematic reviewCrit Care Med200533102184219316215368
   PubMed Web of Science ®Google Scholar
• BouadmaLSonnevilleRGarrouste-OrgeasMOUTCOMEREA Study GroupVentilator-associated events: prevalence, outcome, and relationship with ventilator-associated pneumoniaCrit Care Med20154391798180625978340
   PubMed Web of Science ®Google Scholar
• MicekSJohnsonMTReichleyRKollefMHAn institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsisBMC Infect Dis2012125622414209
   PubMed Web of Science ®Google Scholar
• MicekSTWunderinkRGKollefMHAn international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistanceCrit Care20151921925944081
   PubMed Web of Science ®Google Scholar
• NathwaniDRamanGSulhamKGavaghanMMenonVClinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysisAntimicrob Resist Infect Control2014313225371812
   PubMed Web of Science ®Google Scholar
• VincentJLRelloJMarshallJEPIC II Group of InvestigatorsInternational study of the prevalence and outcomes of infection in intensive care unitsJAMA2009302212323232919952319
   PubMed Web of Science ®Google Scholar
• WangCYJerngJSChenKYPandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomesClin Microbiol Infect2006121636816460548
   PubMed Web of Science ®Google Scholar
• LeroyOd’EscrivanTDevosPDubreuilLKipnisEGeorgesHHospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organismsInfection200533312913515940413
   PubMed Web of Science ®Google Scholar
• Martin-LoechesIDejaMKoulentiDEU-VAP Study InvestigatorsPotentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factorsIntensive Care Med201339467268123358539
   PubMed Web of Science ®Google Scholar
• LuQEggimannPLuytCEPseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomesCrit Care2014181R1724428878
   PubMed Web of Science ®Google Scholar
• SandiumengeALisboaTGomezFHernandezPCanadellLRelloJEffect of antibiotic diversity on ventilator-associated pneumonia caused by ESKAPE organismsChest2011140364365121659436
   PubMed Web of Science ®Google Scholar
• PeñaCGómez-ZorrillaSOriolIImpact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortalityEur J Clin Microbiol Infect Dis201332341342023344827
   PubMed Web of Science ®Google Scholar
• RelloJBorgattaBLisboaTRisk factors for Pseudomonas aeruginosa pneumonia in the early twenty-first centuryIntensive Care Med201339122204220624146002
   PubMed Web of Science ®Google Scholar
• VallésJMariscalDCortésPPatterns of colonization by Pseudomonas aeruginosa in intubated patients: a 3-year prospective study of 1,607 isolates using pulsed-field gel electrophoresis with implications for prevention of ventilator-associated pneumoniaIntensive Care Med20043091768177515243686
   PubMed Web of Science ®Google Scholar
• VeesenmeyerJLHauserARLisboaTRelloJPseudomonas aeruginosa virulence and therapy: evolving translational strategiesCrit Care Med20093751777178619325463
   PubMed Web of Science ®Google Scholar
• RelloJAusinaVRicartMRisk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumoniaIntensive Care Med19942031931988014285
   PubMed Web of Science ®Google Scholar
• RelloJLisboaTKoulentiDRespiratory infections in patients undergoing mechanical ventilationLancet Respir Med20142976477425151022
   PubMed Web of Science ®Google Scholar
• RelloJBorgattaBLagunesLManagement of Pseudomonas aeruginosa pneumonia: one size does not fit allCrit Care201418213625029571
   PubMed Web of Science ®Google Scholar
• RelloJAllegriCRodriguezARisk factors for ventilator-associated pneumonia by Pseudomonas aeruginosa in presence of recent antibiotic exposureAnesthesiology2006105470971417006069
   PubMed Web of Science ®Google Scholar
• RieraJCaraltBLópezIVall d’Hebron Lung Transplant Study GroupVentilator-associated respiratory infection following lung transplantationEur Respir J201545372673725359351
   PubMed Web of Science ®Google Scholar
• RelloJMariscalDMarchFRecurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection?Am J Respir Crit Care Med19981573 Pt 19129169517611
   PubMed Web of Science ®Google Scholar
• VallésJMesallesEMariscalDA 7-year study of severe hospital-acquired pneumonia requiring ICU admissionIntensive Care Med200329111981198813680109
   PubMed Web of Science ®Google Scholar
• American Thoracic Society; Infectious Diseases Society of AmericaGuidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumoniaAm J Respir Crit Care Med2005171438841615699079
   PubMed Web of Science ®Google Scholar
• RobertsJAAbdul-AzizMHLipmanJInternational Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious DiseasesIndividualised antibiotic dosing for patients who are critically ill: challenges and potential solutionsLancet Infect Dis201414649850924768475
   PubMed Web of Science ®Google Scholar
• TacconeFSLaterrePFDugernierTInsufficient β-lactam concentrations in the early phase of severe sepsis and septic shockCrit Care2010144R12620594297
   PubMed Web of Science ®Google Scholar
• RobertsJAPaulSKAkovaMDALI StudyDALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?Clin Infect Dis20145881072108324429437
   PubMed Web of Science ®Google Scholar
• BlotSKoulentiDAkovaMDoes contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI studyCrit Care2014183R9924887569
   PubMed Web of Science ®Google Scholar
• KettDHCanoEQuartinAAImproving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) InvestigatorsImplementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort studyLancet Infect Dis201111318118921256086
   PubMed Web of Science ®Google Scholar
• PlanquetteBTimsitJFMissetBYOUTCOMEREA Study GroupPseudomonas aeruginosa ventilator-associated pneumonia. Predictive factors of treatment failureAm J Respir Crit Care Med20131881697623641973
   PubMed Web of Science ®Google Scholar
• BorgattaBRelloJHow to approach and treat VAP in ICU patientsBMC Infect Dis20141421125430899
   PubMed Web of Science ®Google Scholar
• KumarARobertsDWoodKEDuration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shockCrit Care Med20063461589159616625125
   PubMed Web of Science ®Google Scholar
• FerrerRMartin-LoechesIPhillipsGEmpiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement programCrit Care Med20144281749175524717459
   PubMed Web of Science ®Google Scholar
• SandiumengeADiazEBodíMRelloJTherapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of “The Tarragona Strategy”Intensive Care Med200329687688312677369
   PubMed Web of Science ®Google Scholar
• Garnacho-MonteroJCorcia-PalomoYAmaya-VillarRMartin-VillenLHow to treat VAP due to MDR pathogens in ICU patientsBMC Infect Dis20141413525430700
   PubMed Web of Science ®Google Scholar
• SafdarNHandelsmanJMakiDGDoes combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysisLancet Infect Dis20044851952715288826
   PubMed Web of Science ®Google Scholar
• Garnacho-MonteroJSa-BorgesMSole-ViolanJOptimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapyCrit Care Med20073581888189517581492
   PubMed Web of Science ®Google Scholar
• MokartDSlehoferGLambertJDe-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational studyIntensive Care Med2014401414924231857
   PubMed Web of Science ®Google Scholar
• CapellierGMocklyHCharpentierCEarly-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatmentPLoS One201278e4129022952580
   PubMed Web of Science ®Google Scholar
• ChastreJWolffMFagonJYPneumA Trial GroupComparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trialJAMA2003290192588259814625336
   PubMed Web of Science ®Google Scholar
• VidaurLPlanasKSierraRVentilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilizationChest2008133362563218198250
   PubMed Web of Science ®Google Scholar
• GoldsteinIChastreJRoubyJJNovel and innovative strategies to treat ventilator-associated pneumonia: optimizing the duration of therapy and nebulizing antimicrobial agentsSemin Respir Crit Care Med2006271829116508884
   PubMed Web of Science ®Google Scholar
• LuytCECombesATrouilletJLChastreJValue of the serum procalcitonin level to guide antimicrobial therapy for patients with ventilator-associated pneumoniaSemin Respir Crit Care Med201132218118721506054
   PubMed Web of Science ®Google Scholar
• QuenotJPLuytCERocheNRole of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapyAnn Intensive Care2013312123830525
   PubMed Web of Science ®Google Scholar
• PughRGrantCCookeRPDempseyGShort-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adultsCochrane Database Syst Rev201110CD00757721975771
   PubMed Web of Science ®Google Scholar
• Vazquez-GrandeGKumarAOptimizing antimicrobial therapy of sepsis and septic shock: focus on antibiotic combination therapySemin Respir Crit Care Med201536115416625643278
   PubMed Web of Science ®Google Scholar
• CrandonJLBulikCCKutiJLNicolauDPClinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosaAntimicrob Agents Chemother20105431111111620038614
   PubMed Web of Science ®Google Scholar
• RafatiMRRouiniMRMojtahedzadehMClinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patientsInt J Antimicrob Agents200628212212716815689
   PubMed Web of Science ®Google Scholar
• ChytraIStepanMBenesJClinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trialCrit Care2012163R11322742765
   PubMed Web of Science ®Google Scholar
• LodiseTPJrLomaestroBDrusanoGLPiperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategyClin Infect Dis200744335736317205441
   PubMed Web of Science ®Google Scholar
• LorenteLLorenzoLMartínMMJiménezAMoraMLMeropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilliAnn Pharmacother200640221922316449546
   PubMed Web of Science ®Google Scholar
• LorenteLJiménezAPalmeroSComparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart reviewClin Ther200729112433243918158083
   PubMed Web of Science ®Google Scholar
• DulhuntyJMRobertsJADavisJSContinuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trialClin Infect Dis201356223624423074313
   PubMed Web of Science ®Google Scholar
• KasiakouSKSermaidesGJMichalopoulosASoteriadesESFalagasMEContinuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trialsLancet Infect Dis20055958158916122681
   PubMed Web of Science ®Google Scholar
• RobertsJAWebbSPatersonDHoKMLipmanJA systematic review on clinical benefits of continuous administration of beta-lactam antibioticsCrit Care Med20093762071207819384201
   PubMed Web of Science ®Google Scholar
• MohamedAFKaraiskosIPlachourasDApplication of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial killAntimicrob Agents Chemother20125684241424922615285
   PubMed Web of Science ®Google Scholar
• PeaFBrolloLVialePPavanFFurlanutMTeicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading doseJ Antimicrob Chemother200351497197512654757
   PubMed Web of Science ®Google Scholar
• WangJTFangCTChenYCChangSCNecessity of a loading dose when using vancomycin in critically ill patientsJ Antimicrob Chemother200147224611157921
   PubMed Web of Science ®Google Scholar
• OparaojiECSiramSShoheiberOCornwellEE3rdMezghebeHMAppropriateness of a 4 mg/kg gentamicin or tobramycin loading dose in post-operative septic shock patientsJ Clin Pharm Ther19982331851909831969
   PubMed Web of Science ®Google Scholar
• LuQYangJLiuZGutierrezCAymardGRoubyJJNebulized Antibiotics Study GroupNebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosaAm J Respir Crit Care Med2011184110611521474643
   PubMed Web of Science ®Google Scholar
• LuQLuoRBodinLNebulized Antibiotics Study GroupEfficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumanniiAnesthesiology201211761335134723132092
   PubMed Web of Science ®Google Scholar
• ArnoldHMSawyerAMKollefMHUse of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumoniaRespir Care20125781226123322349038
   PubMed Web of Science ®Google Scholar
• SafdarAShelburneSAEvansSEDickeyBFInhaled therapeutics for prevention and treatment of pneumoniaExpert Opin Drug Saf20098443544919538104
   PubMed Web of Science ®Google Scholar
• WarkPMcDonaldVMNebulised hypertonic saline for cystic fibrosisCochrane Database Syst Rev20092CD00150619370568
   PubMed Web of Science ®Google Scholar
• MichonALJumas-BilakEChironRLamyBMarchandinHAdvances toward the elucidation of hypertonic saline effects on Pseudomonas aeruginosa from cystic fibrosis patientsPLoS One201492e9016424587256
   PubMed Web of Science ®Google Scholar
• BoeJDennisJHO’DriscollBREuropean Respiratory Society Task Force on the use of nebulizersEuropean Respiratory Society Guidelines on the use of nebulizersEur Respir J200118122824211510796
   PubMed Web of Science ®Google Scholar
• DuijvestijnYCBrandPLSystematic review of N-acetylcysteine in cystic fibrosisActa Paediatr1999881384110090545
   PubMed Web of Science ®Google Scholar
• BassettiMMerelliMTemperoniCAstileanANew antibiotics for bad bugs: where are we?Ann Clin Microbiol Antimicrob2013122223984642
   PubMed Web of Science ®Google Scholar
• SaderHSCastanheiraMFlammRKFarrellDJJonesRNAntimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from US medical centers in 2012Antimicrob Agents Chemother20145831684169224379201
   PubMed Web of Science ®Google Scholar
• BustosCDel PozoJLEmerging agents to combat complicated and resistant infections: focus on ceftobiproleInfect Drug Resist2010351421694889
   PubMedGoogle Scholar
• FarrellDJFlammRKSaderHSJonesRNCeftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010Antimicrob Agents Chemother20145873882388824777091
   PubMed Web of Science ®Google Scholar
• AwadSSRodriguezAHChuangYCA phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumoniaClin Infect Dis2014591516124723282
   PubMed Web of Science ®Google Scholar
• LahiriSDManganiSDurand-RevilleTStructural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamasesAntimicrob Agents Chemother20135762496250523439634
   PubMed Web of Science ®Google Scholar
• Lagacé-WiensPWalktyAKarlowskyJACeftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infectionsCore Evid20149132524493994
   PubMedGoogle Scholar
• CurcioDMultidrug-resistant Gram-negative bacterial infections: are you ready for the challenge?Curr Clin Pharmacol201491273823489027
   PubMedGoogle Scholar
• HousmanSTCrandonJLNicholsWWNicolauDPEfficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection modelAntimicrob Agents Chemother20145831365137124342641
   PubMed Web of Science ®Google Scholar
• LevasseurPGirardAMClaudonMIn vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolatesAntimicrob Agents Chemother20125631606160822214778
   PubMed Web of Science ®Google Scholar
• CrandonJLSchuckVJBaneviciusMAComparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosaAntimicrob Agents Chemother201256126137614622985878
   PubMed Web of Science ®Google Scholar
• VazquezJAGonzález PatzánLDStricklinDEfficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized studyCurr Med Res Opin201228121921193123145859
   PubMed Web of Science ®Google Scholar
• LucastiCPopescuIRameshMKLipkaJSableCComparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trialJ Antimicrob Chemother20136851183119223391714
   PubMed Web of Science ®Google Scholar
• AstraZenecaA Study Comparing Ceftazidime-Avibactam Versus MeropenemHospitalized Adults With Nosocomial Pneumonia Available from: https://clinicaltrials.gov/ct2/show/NCT1808092. NLM identifier: NCT1808092Accessed February 26, 2015
   Google Scholar
• HongMCHsuDIBounthavongMCeftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combinationInfect Drug Resist2013621522324348053
   PubMedGoogle Scholar
• TakedaSNakaiTWakaiYIkedaFHatanoKIn vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosaAntimicrob Agents Chemother200751382683017145788
   PubMed Web of Science ®Google Scholar
• WalktyAKarlowskyJAAdamHIn vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012Antimicrob Agents Chemother201357115707570923939895
   PubMed Web of Science ®Google Scholar
• MoyaBZamoranoLJuanCPérezJLGeYOliverAActivity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patientsAntimicrob Agents Chemother20105431213121720086158
   PubMed Web of Science ®Google Scholar
• ChandorkarGHuntingtonJAGotfriedMHRodvoldKAUmehOIntrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjectsJ Antimicrob Chemother201267102463246922773741
   PubMed Web of Science ®Google Scholar
• SolomkinJHershbergerEMillerBCeftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)Clin Infect Dis201560101462147125670823
   PubMed Web of Science ®Google Scholar
• MatsumotoTArbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogensClin Pharmacol2014613914825298740
   PubMedGoogle Scholar
• Calixa Therapeutics, Inc.Safety and Efficacy of IV CXA-101 and IV CeftazidimePatients With Complicated Urinary Tract Infections Available from https://clinicaltrials.gov/ct2/show/study/NCT0921024. NLM identifier: NCT0921024Accessed February 28, 2015
   Google Scholar
• Cubist Pharmaceuticals Holdings LLCStudy of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/TazobactamVentilator-Associated Pneumonia Available from: https://clinicaltrials.gov/ct2/show/NCT1853982. NLM identifier: NCT1853982Accessed February 28, 2015
   Google Scholar
• AraokaHBabaMTatedaKABX Combination Therapy Study GroupIn vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in JapanJpn J Infect Dis2012651848722274165
   PubMed Web of Science ®Google Scholar
• FunatsuYHasegawaNFujiwaraHPharmacokinetics of arbekacin in bronchial epithelial lining fluid of healthy volunteersJ Infect Chemother2014201060761124973909
   PubMed Web of Science ®Google Scholar
• SrinivasNJetterPUeberbacherBJPeptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosaScience201032759681010101320167788
   PubMed Web of Science ®Google Scholar
• Antibiotic POL7080 [webpage on the Internet]AllschwilPolyphor Ltd [updated March 25, 2015]. Available from: http://www.polyphor.com/products/pol7080Accessed March 29, 2015
   Google Scholar
• Polyphor LtdPharmacokinetics, Safety and Efficacy of POL7080Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia Available from: https://clinicaltrials.gov/ct2/show/NCT2096328. NLM identifier: NCT2096328Accessed March 1, 2015
   Google Scholar
• HustonWMPotterAJJenningsMPRelloJHauserARMcEwanAGSurvey of ferroxidase expression and siderophore production in clinical isolates of Pseudomonas aeruginosaJ Clin Microbiol20044262806280915184477
   PubMed Web of Science ®Google Scholar
• BattleSEMeyerFRelloJKungVLHauserARHybrid pathogenicity island PAGI-5 contributes to the highly virulent phenotype of a Pseudomonas aeruginosa isolate in mammalsJ Bacteriol2008190217130714018757543
   PubMed Web of Science ®Google Scholar
• BattleSERelloJHauserARGenomic islands of Pseudomonas aeruginosaFEMS Microbiol Lett20092901707819025565
   PubMed Web of Science ®Google Scholar
• LavertyGGormanSPGilmoreBFBiomolecular mechanisms of Pseudomonas aeruginosa and Escherichia coli biofilm formationPathogens20143359663225438014
   PubMedGoogle Scholar
• SharmaGRaoSBansalADangSGuptaSGabraniRPseudomonas aeruginosa biofilm: potential therapeutic targetsBiologicals20144211724309094
   PubMed Web of Science ®Google Scholar
• LeidJGWillsonCJShirtliffMEHassettDJParsekMRJeffersAKThe exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-gamma-mediated macrophage killingJ Immunol2005175117512751816301659
   PubMed Web of Science ®Google Scholar
• GellatlySLHancockREPseudomonas aeruginosa: new insights into pathogenesis and host defensesPathog Dis201367315917323620179
   PubMed Web of Science ®Google Scholar
• MaiGTMcCormackJGSeowWKPierGBJacksonLAThongYHInhibition of adherence of mucoid Pseudomonas aeruginosa by alginase, specific monoclonal antibodies, and antibioticsInfect Immun19936110433843438406822
   PubMed Web of Science ®Google Scholar
• PierGBBoyerDPrestonMHuman monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strainsJ Immunol200417395671567815494518
   PubMed Web of Science ®Google Scholar
• SordéRPahissaARelloJManagement of refractory Pseudomonas aeruginosa infection in cystic fibrosisInfect Drug Resist20114314121694907
   PubMedGoogle Scholar
• JuhasMEberlLTümmlerBQuorum sensing: the power of cooperation in the world of PseudomonasEnviron Microbiol20057445947115816912
   PubMed Web of Science ®Google Scholar
• de KievitTRQuorum sensing in Pseudomonas aeruginosa biofilmsEnviron Microbiol200911227928819196266
   PubMed Web of Science ®Google Scholar
• WhiteleyMLeeKMGreenbergEPIdentification of genes controlled by quorum sensing in Pseudomonas aeruginosaProc Natl Acad Sci U S A19999624139041390910570171
   PubMed Web of Science ®Google Scholar
• LespritPFaurissonFJoin-LambertORole of the quorum-sensing system in experimental pneumonia due to Pseudomonas aeruginosa in ratsAm J Respir Crit Care Med2003167111478148212569080
   PubMed Web of Science ®Google Scholar
• HraiechSHiblotJLafleurJInhaled lactonase reduces Pseudomonas aeruginosa quorum sensing and mortality in rat pneumoniaPLoS One2014910e10712525350373
   PubMed Web of Science ®Google Scholar
• SatoHFrankDWMulti-functional characteristics of the Pseudomonas aeruginosa type III needle-tip protein, PcrV; comparison to orthologs in other gram-negative bacteriaFront Microbiol2011214221772833
   PubMed Web of Science ®Google Scholar
• SawaTItoENguyenVHHaightMAnti-PcrV antibody strategies against virulent Pseudomonas aeruginosaHum Vaccin Immunother201410102843285225483637
   PubMed Web of Science ®Google Scholar
• LynchSVFlanaganJLSawaTPolymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV – implications for anti-PcrV immunotherapyMicrob Pathog201048619720420211240
   PubMed Web of Science ®Google Scholar
• HauserARCobbEBodiMType III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosaCrit Care Med200230352152811990909
   PubMed Web of Science ®Google Scholar
• SchulertGSFeltmanHRabinSDSecretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumoniaJ Infect Dis2003188111695170614639541
   PubMed Web of Science ®Google Scholar
• GoureJPastorAFaudryEChabertJDessenAAttreeIThe V antigen of Pseudomonas aeruginosa Is required for assembly of the functional PopB/PopD translocation pore in host cell membranesInfect Immun20047284741475015271936
   PubMed Web of Science ®Google Scholar
• WangQLiHZhouJPcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injuryRespir Physiol Neurobiol2014193212824418353
   PubMed Web of Science ®Google Scholar
• WarrenerPVarkeyRBonnellJCA novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection modelsAntimicrob Agents Chemother20145884384439124841258
   PubMed Web of Science ®Google Scholar
• ShimeNSawaTFujimotoJTherapeutic administration of anti-PcrV F(ab’)(2) in sepsis associated with Pseudomonas aeruginosaJ Immunol2001167105880588611698464
   PubMed Web of Science ®Google Scholar
• FrançoisBLuytCEDugardASafety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trialCrit Care Med20124082320232622622405
   PubMed Web of Science ®Google Scholar
• NakagawaAHosoyamaTChubachiKTakahashiSOhkuboTIyobeSA search for Pseudomonas alginate biosynthesis inhibitors from microbial metabolitesJ Antibiot (Tokyo)1997503286288
   Web of Science ®Google Scholar
• OliverAMWeirDMThe effect of Pseudomonas alginate on rat alveolar macrophage phagocytosis and bacterial opsonizationClin Exp Immunol19855911901963918817
   PubMed Web of Science ®Google Scholar
• ZaidiTPierGBProphylactic and therapeutic efficacy of a fully human immunoglobulin G1 monoclonal antibody to Pseudomonas aeruginosa alginate in murine keratitis infectionInfect Immun200876104720472518644881
   PubMed Web of Science ®Google Scholar
• de KievitTRLamJSMonoclonal antibodies that distinguish inner core, outer core, and lipid A regions of Pseudomonas aeruginosa lipopolysaccharideJ Bacteriol199417623712971397525538
   PubMed Web of Science ®Google Scholar
• LazarHHornMPZuercherAWPharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteersAntimicrob Agents Chemother20095383442344619451304
   PubMed Web of Science ®Google Scholar
• LuQRoubyJJLaterrePFPharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumoniaJ Antimicrob Chemother20116651110111621398296
   PubMed Web of Science ®Google Scholar
• Summary of AR-101 clinical data [webpage on the Internet]San JoseAridis Pharmaceuticals Available from: http://www.aridispharma.com/ar101clinicaldata.htmlAccessed June 7, 2015
   Google Scholar
• SharmaAKrauseAWorgallSRecent developments for Pseudomonas vaccinesHum Vaccin2011710999101121941090
   PubMed Web of Science ®Google Scholar
• PierGApplication of vaccine technology to prevention of Pseudomonas aeruginosa infectionsExpert Rev Vaccines20054564565616221066
   PubMed Web of Science ®Google Scholar
• BaumannUMansouriEvon SpechtBURecombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infectionsVaccine200422784084715040936
   PubMed Web of Science ®Google Scholar
• von SpechtBUKnappBMuthGProtection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteinsInfect Immun1995635185518627729895
   PubMed Web of Science ®Google Scholar
• SorichterSBaumannUBaumgartAWalterspacherSvon SpechtBUImmune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung diseaseVaccine200927212755275919366571
   PubMed Web of Science ®Google Scholar
• MansouriEBlome-EberweinSGabelsbergerJGermannGvon SpechtBUClinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patientsFEMS Immunol Med Microbiol2003372–316116612832120
   PubMed Web of Science ®Google Scholar
• MansouriEGabelsbergerJKnappBSafety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteersInfect Immun19996731461147010024596
   PubMed Web of Science ®Google Scholar
• Valneva Austria GmbHStudy Assessing Immunogenicity and Safety of IC43Intensive Care Patients Available from: https://clinicaltrials.gov/ct2/show/NCT0876252. NLM identifier: NCT0876252Accessed April 6, 2015
   Google Scholar
• IntercellA confirmatory phase II/III study assesing efficacy, immunogenecity and safety of IC43 recombinant Pseudomonas vaccie in intensive care patients Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004771-36/ES. EudraCT identifier: 2011-004771-36Accessed April 6, 2015
   Google Scholar